A Phase 3, randomised, double-blind, parallel-group, event driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD

• Código protocolo: 1404-0040
• Código EudraCT: No aplica
• Grupo de investigación: Diabetes y Metabolismo
• Servicio: Endocrinología
• Investigador/a principal:  Simó Canonge, Rafael
• Patología: Malalties endocrines, nutricionals i metabòliques
• Fase: Fase III
• Estado: Reclutando voluntarios